Advertisement

Reactions Weekly

, Volume 1738, Issue 1, pp 198–198 | Cite as

Norethisterone/oxaliplatin

Veno-occlusive disease: 7 case reports
Case report
  • 20 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a study, seven patients (three women and four men) aged 54−63 years were described, who developed veno-occlusive disease (VOD) following treatment with oxaliplatin for follicular lymphoma, diffuse large B-cell lymphoma or mantle cell lymphoma. One of the seven patients was additionally receiving norethisterone [dosages, routes and durations of treatments to reactions onsets not stated; not all outcomes stated].

Case 1: A 54-year-old woman had been diagnosed with grade I-II follicular lymphoma in 2010. Following first line chemotherapy, the disease relapsed in March 2015; she started receiving inductive salvage therapy with R-DHAOx regimen including oxaliplatin, every 3 weeks. She was enrolled in a clinical trial and underwent an autologous stem cell transplantation following...

Reference

  1. Debureaux P-E, et al. Veino-occlusive disease (VOD) during autologous stem cell transplantation (ASCT): Warning about suspected increased incidence after oxaliplatin-containing salvage regimen. HemaSphere 2 (Suppl. 1): 815-816 abstr. PB1785, Jun 2018. Available from: URL: http://doi.org/10.1097/HS9.0000000000000060 [abstract] - France

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations